CACI

In the past six months (March 2026 - September 2026), CACI's stock was impacted by strong financial results for fiscal Q4 and full year ended June 30, 2026, reporting diluted EPS of $8.91 (beating estimates by $1.52) and revenue increasing 17.6% year-over-year to $2.71 billion (exceeding expectations). For the full fiscal year 2026, revenues increased 10.9% to $9.6 billion, and net income rose 7.2% to $535.8 million. The company also issued positive fiscal year 2027 guidance. CACI secured significant contract awards, including a $1.5 billion award to support U.S. Central Command (USCENTCOM) in September 2026, a contract to advance U.S. Space Force test and training technology in August 2026, and a contract increase of over $140 million for forensic exploitation support to the U.S. Army DEVCOM C5ISR Center in August 2026, bringing the total contract value to over $560 million. Analyst sentiment has been generally positive with a 'Buy' consensus rating, and the stock price passed above its 200-day moving average in September 2026.